Tag Archives: SELECT Trial

AHA 2023

AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

Given the obesity pandemic projected for the year 2035, it is imperative to address this disease as a priority, through well-known hygienic-dietary measures and the use of drugs that have shown promising results. Obesity has been identified as an independent cardiovascular risk factor, even after modifying risk factors associated with diabetes. Semaglutide, a GLP-1 agonist,

Top